A comparison of alternate immunization regimes for measles in vaccinated populations

Vaccine

Volumn 17, Issue 2, 1999, Pages 182-192

  Pabst, H F ^a   Boothe, P M ^a   Carson, M M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cost savings; Measles; MMR

Indexed keywords

MATERNAL ANTIBODY; MEASLES MUMPS RUBELLA VACCINE;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COST CONTROL; DRUG EFFICACY; HUMAN; IMMUNITY; INFANT; MEASLES; MEASLES VACCINATION; MODEL; PRIORITY JOURNAL; SEROCONVERSION;

ALBERTA; ANTIBODIES, VIRAL; COSTS AND COST ANALYSIS; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION SCHEDULE; INFANT; MEASLES; MEASLES VACCINE; MEASLES VIRUS; NEUTRALIZATION TESTS; PREGNANCY;

EID: 0032889656     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00158-3     Document Type: Article

References (33)

1. Atkinson WL, Hadler SC, Redd SB Orenstein WA, Measles surveillance - United States, 1991. MMWR 1992;41(SS-6):1-12.
2. Laboratory Centre for Disease Control. Concensus Conference on measles.CCDR,1993, 19, 27-29.
3. Centers for Disease Control. Reported vaccine-preventable diseases - United States, 1993, and the Childhood Immunization Initiative. MMWR, 1994, 43, 57-60.
4. Centers for Disease Control and Prevention. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. MMWR, 1997, 46(RR-11), 1-20.
5. Centers for Disease Control. Measles - United States, 1995. MMWR, 1996, 45,305-307.
6. Centers for Disease Control and Prevention. Measles - United States, 1996, and the interruption of indigenous transmission. MMWR, 1997, 46, 242-246.
7. Pabst H.F., Spady D.W., Marusyk R.G.et al. Reduced measles immunity in infants in a well-vaccinated population. Pediatric Infectious Diseases Journal. 11:1992;525-529.
8. Bromberg K., Shah B., Clark-Golden M.et al. Maternal immunity to measles and infant immunity at less than twelve months of age relative to maternal place of birth. Journal of Pediatrics. 125:1994;579-581.
9. Kacica M.A., Venezia R.A., Miller J.et al. Measles antibodies in women and infants in the vaccine era. Journal of Medicine and Virology. 45:1995;227-229.
10. Maldonado Y.A., Lawrence E.C., DeHovitz R.et al. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics. 96:1995;447-450.
11. Markowitz L.E., Albrecht P., Rhodes P.et al. Changing levels of measles antibody titers in women and children in the United States: impact of response to vaccination. Pediatrics. 97:1996;53-58.
12. Albrecht P., Ennis F.A., Saltzman E.J.et al. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. Journal of Pediatrics. 91:1977;715-718.
13. Centers for Disease Control. Measles - United States, 1994. MMWR, 44, 486-494.
14. Centers for Disease Control. Measles - United States, 1992. MMWR, 1993, 42, 378-381.
15. Carson M.M., Spady D.W., Albrecht P.et al. Measles vaccination of infants in a well-vaccinated population. Pediatric Infectious Diseases Journal. 14:1995;17-22.
16. Albrecht P., Herrman K., Burns G.R. Role of virus strain in conventional and enhanced measles plaque neutralization test. Journal of Virology Methods. 3:1981;251-260.
17. Chen R.T., Markowitz L.E., Albrecht P.et al. Measles antibody: re-evaluation of protective titers. Journal of Infectious Diseases. 162:1990;1036-1042.
18. Johnson C.E., Nalin D.R., Chui L.W., Whitwell J., Marusyk R.G., Kumar M.L. Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics. 93:1994;939-943.
19. Bolotovsky V.M., Grabowsky M., Clements C.J.et al. Immunization of 6 and 9-month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. International Journal of Epidemiology. 23:1994;1069-1077.
20. Krugman R.D., Rosenberg R., McIntosh K.et al. Further attenuated live measles vaccines: the need for revised recommendations. Journal of Pediatrics. 91:1977;766-767.
21. Ratnam S., West R., Gadag V.et al. Measles antibody response following MMR II immunization of Newfoundland infants. LCDC Measles. 2:1994;4.
22. Williams B.G., Cutts F.T., Dye C. Measles vaccination policy. Epidemiology and Infection. 115:1995;603-621.
23. Gindler J.S., Atkinson W.L., Markowitz L.E.et al. Epidemiology of measles in the United States in 1989 and 1990. Pediatric Infectious Diseases Journal. 11:1992;841-846.
24. Miller C., Farrington C.P., Harbert K. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970-1989. International Journal of Epidemiology. 21:1992;998-1006.
25. Wilkens J., Wehrle P.F. Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization. Journal of Pediatrics. 94:1979;865-869.
26. Black F.L., Berman L.L., Libel M.et al. Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bulletin WHO. 62:1984;315-319.
27. Hayney M.S., Poland G.A., Dimanlig R.et al. Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine. 15:1997;3-6.
28. Pabst H.F., Krezolek M., Pilarski L.M.et al. Immunomodulation of the infant immune response by breast feeding. Acta Pediatrica. 86:1997;1291-1297.
29. Samb B., Aaby P., Whittle H.C.et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatric Infectious Diseases Journal. 14:1995;203-209.
30. Edmonson M.B., Addiss D.G., McPherson J.T.et al. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA. 263:1990;2467-2471.
31. Olsen L.F., Schaffer W.M. Chaos versus noisy periodicity: Alternative hypothesis for childhood epidemics. Science. 249:1990;499-504.
32. Sidorowich J.J. Repellors attract attention. Nature. 355:1995;584-585.
33. Wyde P.R., Nagendra R., Kemp A.et al. Infection of leucocytes by measles vaccine viruses Edmonston-Zagreb and Enders-Moraten has different consequences: potential mechanism for increased vaccine efficacy or aberrant activity in field trials. Vaccine. 12:1994;715-722.